Healthcare -
Medical - Diagnostics & Research - NASDAQ - US
$ 1.78
-3.78 %
$ 12.3 M
Market Cap
-1.34
P/E
1. INTRINSIC VALUE
Balance Sheet
Intelligent Bio Solutions Inc.
| Current Assets | 8.53 M |
| Cash & Short-Term Investments | 6.3 M |
| Receivables | 978 K |
| Other Current Assets | 1.25 M |
| Non-Current Assets | 5.24 M |
| Long-Term Investments | 0 |
| PP&E | 873 K |
| Other Non-Current Assets | 4.37 M |
| Current Liabilities | 5.45 M |
| Accounts Payable | 602 K |
| Short-Term Debt | 1.06 M |
| Other Current Liabilities | 3.78 M |
| Non-Current Liabilities | 145 K |
| Long-Term Debt | 81.3 K |
| Other Non-Current Liabilities | 63.6 K |
EFFICIENCY
Earnings Waterfall
Intelligent Bio Solutions Inc.
| Revenue | 3.11 M |
| Cost Of Revenue | 1.69 M |
| Gross Profit | 1.43 M |
| Operating Expenses | 11.7 M |
| Operating Income | -10.3 M |
| Other Expenses | -92.1 K |
| Net Income | -10.2 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Intelligent Bio Solutions Inc.
| Net Income | -10.2 M |
| Depreciation & Amortization | 1.21 M |
| Capital Expenditures | -221 K |
| Stock-Based Compensation | 230 K |
| Change in Working Capital | -702 K |
| Others | -258 K |
| Free Cash Flow | -9.79 M |
Wall Street Analysts Price Targets
Intelligent Bio Solutions Inc.
INBS has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
INBS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Intelligent Bio Solutions Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Intelligent Bio Solutions Launches In-House Fingerprint Drug Testing Across 20+ Sites for Major Australian Waste Operator, Accelerating APAC Expansion
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Managed Waste Service (“MWS”), a leading Australian waste management provider, plans to implement INBS' Intelligent Fingerprinting Drug Screening System across its New South Wales operations, including its land clearing and green waste processing sites.
globenewswire.com
- 3 days ago
INBS Stock May Rise on SMARTOX Partnership Expanding Forensic Reach
Intelligent Bio Solutions collaborates with SMARTOX to expand U.S. forensic reach, boosting its drug test tech and eyeing FDA clearance for growth.
zacks.com
- 5 days ago
Intelligent Bio Solutions Expands U.S. Forensic Market Presence, Seeks FDA Clearance for Breakthrough Fingerprint Drug Testing
SMARTOX has deployed over 50 of INBS' Intelligent Fingerprinting Drug Screening Readers and facilitated over 7,000 screening tests, including more than 1,500 tests in 2024 alone
globenewswire.com
- 1 week ago
Intelligent Bio Solutions to Showcase Fingerprint Drug Testing at RISE25 Conference from May 28-31, Supporting Innovation in U.S. Forensic Drug Testing
INBS to participate with U.S. distribution partner SMARTOX at RISE25, the leading U.S. conference on addiction, mental health, and justice innovation which draws over 7,000 attendees annually
globenewswire.com
- 4 weeks ago
Intelligent Bio Solutions Showcases Rapid, Non-Invasive Drug Testing Capabilities in Remote Queensland Workforce Deployment
Completion of 160 tests conducted in less than 90 minutes demonstrates a level of speed and efficiency beyond the limits of traditional testing approaches Completion of 160 tests conducted in less than 90 minutes demonstrates a level of speed and efficiency beyond the limits of traditional testing approaches
globenewswire.com
- 1 month ago
Intelligent Bio Solutions Accelerates Global Adoption of Fingerprint Drug Testing
Company surpasses 450 accounts across 24 countries as global demand for fingerprint drug testing surges Company surpasses 450 accounts across 24 countries as global demand for fingerprint drug testing surges
globenewswire.com
- 1 month ago
Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements
20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025 35 new accounts and international growth during Q3 bring total active accounts to over 450 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal third quarter and nine months ended March 31, 2025, and provided a business update. The Company delivered a strong quarter of growth in revenue compared to the previous quarter, supported by ongoing expansion across safety-critical industries and steady customer acquisition.
globenewswire.com
- 1 month ago
Intelligent Bio Solutions Drives Global Growth Through Multilingual Digital Expansion
Arabic, Italian, and Spanish-language websites unlock commercial access to regions representing over 1.4 billion people Multilingual rollout aligns with product readiness and accelerates international sales pipeline development NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the launch of three new localized websites in Arabic, Italian, and Spanish. This rollout supports the Company's global growth plans and international sales expansion by opening digital and commercial access to some of the world's fastest-growing, high-demand regions for workplace safety and compliance solutions.
globenewswire.com
- 1 month ago
Intelligent Bio Solutions Expands Global Reach with Latin American Spanish Language Integration into Drug Screening System
Company expands Intelligent Fingerprinting Drug Screening System multilingual capabilities to meet growing demand across Latin American Spanish-speaking markets
globenewswire.com
- 1 month ago
Intelligent Bio Solutions Expands Middle East Market Reach with Arabic Integration in Drug Screening System
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has integrated Arabic as the second international language to its Intelligent Fingerprinting Drug Screening System as part of the Company's multilingual upgrade. The addition of Arabic follows INBS's previously announced expansion plans in the Middle East in early 2025, through its partnership with Ivy Diagnostics.
globenewswire.com
- 2 months ago
Intelligent Bio Solutions to Highlight Proprietary Drug Testing Technology at 2025 NDASA Conference and Trade Show
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its participation as a gold sponsor at the 2025 National Drug and Alcohol Screening Association (NDASA) Conference and Trade Show, taking place from April 1 – 4 in Jacksonville, Florida. Daniel Brown, Head of Clinical Affairs at Intelligent Bio Solutions, will present at the International Symposium on Tuesday, April 1, at 1:00 PM.
globenewswire.com
- 2 months ago
Intelligent Bio Solutions Stock Drops Despite Key U.S. Patent Win
INBS secures a key U.S. patent, strengthening its IP protection and paving the way for 2025 market entry with innovative biometric technology.
zacks.com
- 2 months ago
8. Profile
Summary
Intelligent Bio Solutions Inc. INBS
COUNTRY
US
INDUSTRY
Medical - Diagnostics & Research
MARKET CAP
$ 12.3 M
Dividend Yield
0.00%
Description
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Contact
142 West 57th Street, New York City, NY, 10019
https://gbs.inc
IPO
Date
Dec. 23, 2020
Employees
50
Officers
Callistus Sequeira
Vice President of Global Quality & Operations
Mr. Doug Heath
Vice President of Global Sales
Anna Turkington
Vice President of Marketing
Mr. Harry Simeonidis
President & Chief Executive Officer
Mr. Spiro Kevin Sakiris B.Bus, C.A., CA, Dip Law
Chief Financial Officer